Shaanxi Micot Pharmaceutical Technology (HKG:2335) concluded the phase II clinical trial of MT200605 for the treatment of AIS, according to a Wednesday Hong Kong bourse filing.
Shares of the Chinese biotechnology company were up nearly 2% in Thursday afternoon trading.
The trial demonstrated significant and robust efficacy advantages with a favorable safety profile.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.